BioCryst agrees to sell European ORLADEYO business to Neopharmed Gentili for $250M

BIOCRYST PHARMACEUTICALS INC

Upfront cash consideration of $250M plus up to $14M in revenue milestones if achieved before Dec 31, 2032.
Transaction expected to close in October 2025, subject to antitrust clearance and customary closing conditions.
BioCryst will continue as exclusive supplier of ORLADEYO under a supply agreement and enter IP license, brand support, and transition services agreements.
Sale includes all equity of BioCryst Ireland Limited, which holds European ORLADEYO assets and rights.
The amended IP license may extend to the pediatric line extension of ORLADEYO subject to regulatory approvals.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.